Purpose: The purpose of the present study is to evaluate safety, human radiation dosimetry, and optimal imaging time of [ 89 Zr]trastuzumab in patients with HER2-positive breast cancer.
Introduction
Human epidermal growth factor receptor 2 (HER2) has an important role in cell survival, proliferation, angiogenesis, and development of metastasis [1] . HER2-positive tumors account for approximately 20-25 % of all cases of breast cancer. Prior to the development of HER2-targeted therapy, HER2-positive breast cancer had the worst prognosis of all breast cancer subtypes [2, 3] . Trastuzumab, a humanized monoclonal antibody (mAb) targeting HER2, has significantly improved patient survival, but the development of drug resistance is still a significant medical challenge [4, 5] . In fact, the majority of metastatic HER2-positive breast cancer will develop trastuzumab resistance over the course of treatment [6] .
Currently, two types of tests are available to measure HER2 in breast cancer biopsies. Immunohistochemistry (IHC) detects HER2 overexpression, and fluorescence in situ hybridization (FISH) detects HER2 gene amplification [7] [8] [9] . There is evidence that HER2 status may change during the course of the disease and after chemotherapy [10] . In addition, discordance in HER2 expression across tumor lesions in the same patient has been reported [11] [12] [13] [14] . Thus, the use of repeated biopsies during the course of the disease is encouraged [15] . However, repeated invasive biopsies are often not clinically feasible, and not all lesions are readily accessible for biopsy [16] . Therefore, a method that can address tumor heterogeneity and reliably determine both the quantity and the functional status of tumor HER2 in individual lesions in a noninvasive manner is of critical importance in identifying patients who would benefit from HER2-targeted therapy and to monitor the change in HER2 status during therapy.
Positron emission tomography (PET)-based measurement of the HER2 expression in breast cancer offers several advantages over current biopsy-based methods. These include assessing HER2 expression of the entire tumor volume rather than just a part of the tumor (addressing the intrinsic heterogeneity of HER2 expression), directly assessing the binding of the therapeutic mAb (trastuzumab) to HER2, and evaluating the effects of therapy on HER2 expression of the tumor. In addition, imaging can simultaneously assess HER2 expression of primary and metastatic sites, which may vary across lesions within any given patient. PET is a highly sensitive functional imaging technique that has the ability for quantification at subnanomolar concentrations. PET with radiolabeled mAbs can be used for noninvasive detection and quantification of specific targets throughout the body and ultimately can help to better understand the behavior and effectiveness of treatment with mAbs in individual patients. Several [17] [18] [19] [20] [21] [22] [23] [24] .
Of the positron-emitting radiometals, Zr-89 (EC = 76.6 %, β+= 22.3 %, E ave. (β+) = 396.9 keV, R ave. (β+) = 1.18 mm) has an optimal half-life (78.4 h) for imaging mAbs, allowing for imaging up to 7 days after injection. In this study, we aimed to evaluate the human radiation dosimetry of [ 89 Zr]trastuzumab based on PET imaging results and to determine the optimal imaging time with this agent in patients with HER2-positive breast cancer. 89 Zr]trastuzumab, was sterile filtered through a 0.2-μm filter and diluted with saline through the same sterile filter to a final volume of 10 ml. The radiochemical yield was determined to be ≥95 % by radio-ITLC using 50 mM DTPA as the developing solution. The antibody aggregation analysis was determined using size-exclusion chromatography (Superose 12 10/300 GL, GE Healthcare, Piscataway, NJ), resulting in ≥80 % [
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89 Zr]trastuzumab monomer. Radionuclide identity, visual appearance, pH, specific activity, and bubble point filter membrane integrity were determined pre-release. The immunoreactivity assay was performed on HER2+ SKBR3 human breast cancer cells following methods developed by Lindmo et al. [29] , where we achieved an average immunoreactive fraction of 89 ± 0.1 % (acceptance criterion is ≥ 65 %). The immunoreactivity assay and sterility of the final product were determined post-release.
PET Imaging Procedures
All PET imaging was performed with a Siemens Biograph 40 PET/CT scanner. Whole-body PET imaging was performed at two separate time points within 7 days (1 and 3 days, 2 and 5 days, and 4 and 6 days) following [
89 Zr]trastuzumab injection (day 0). Trastuzumab-naive subjects were dosed with 50 mg Bcoldt rastuzumab, whereas those undergoing trastuzumab therapy received 10 mg, 30 min to 2 h before administration of 62 ± 2 MBq (1.76 ± 0.50 mCi) of [ 89 Zr]trastuzumab; these pre-doses have been shown by Dijkers et al. to be adequate for minimizing uptake of radiolabeled trastuzumab by normal organs [18] . The administered activity was expected to result in an effective dose (ED) of 50 mSv based on mouse radiation dosimetry (Supplementary data). All subjects were monitored for possible infusion reaction (i.e., dyspnea, chest tightness, fever, rigors, or hypotension) during trastuzumab and [
89 Zr]trastuzumab administration. In addition, all patients underwent measurement of vital signs (blood pressure, heart rate, respiratory rate, and temperature), clinical laboratory testing (standard hematologic and comprehensive metabolic panels that included hemoglobin, white blood cells, neutrophils, lymphocytes, platelets, creatinine, blood urea nitrogen, calcium, sodium, potassium, carbon dioxide, alanine transaminase, aspartate aminotransferase, alkaline phosphatase, total bilirubin, and albumin), urinalysis, and electrocardiography before [
89 Zr]trastuzumab administration and at the second imaging session.
A spiral CT scan for attenuation correction (120 kVp, 50 effective mAs at 5-mm slice thickness) was obtained from the top of the skull through the upper thighs with the subject in the supine position. Immediately after the attenuation CT scan, emission images beginning at the top of the skull and proceeding down through the upper thighs were obtained (1-10 min per bed position depending on the time postinjection). Imaging was performed over six to seven bed positions with a total imaging duration of no more than 1 h. Images were reconstructed with 3D-OSEM with three iterations, 24 subsets, and a post-reconstruction Gaussian filter of 7 mm.
Image Analysis
All images were evaluated subjectively by one observer, who was blinded to the time of imaging for assessment of image quality (graded on a four-point scale, with 1 being poor quality-not acceptable for diagnostic interpretation-and 4 being good image quality-similar to a routine clinical study). The images were then evaluated to assess the uptake of [ 89 Zr]trastuzumab in known sites of disease (based on all available imaging studies).
Image-Derived Patient Dosimetry
Organ activity concentration data were obtained by drawing regions of interest (ROIs) on the PET images for the following organs/ tissues: liver, kidneys, blood (left ventricular chamber), spleen, muscle, subcutaneous fat, and red marrow. The red marrow activity concentrations were determined from the average activity concentration measured in the lumbar vertebrae. The total activity in each organ was then calculated as the product of the activity concentration and the standard adult female organ weight. Organ timeactivity curves were created by collating the decay-corrected data from all patients fitted by mono-exponential functions. Analytical integration of the fit provided the organ residence times. Total patient blood volume was determined by the method of Lemmens et al. [30] . The remainder of the body residence time was determined from the maximum theoretical residence time minus the sum of the residence times observed in the organs (except for fat and blood); accordingly, this conservative approach assumed no excretion. Human dosimetry estimates were obtained from the residence times using OLINDA/EXM version 1.1 software with the adult female model.
Results
Patient Characteristics
Twelve women (mean ± standard deviation: 57.0 ± 22.2 years; range 29 to 71 years) were enrolled in the study. Six had primary breast cancer and six had metastatic breast cancer. Eleven subjects underwent [ 89 Zr]trastuzumab PET/CT during neoadjuvant or adjuvant therapy; the remaining subject was studied before initiation of neoadjuvant therapy. Ten of the 12 subjects were receiving trastuzumab while participating in this trial and, thus, received the 10-mg pre-dose of cold trastuzumab while the other 2 were not receiving trastuzumab therapy and received a 50-mg pre-dose.
Safety Evaluation
The mean administered activity was 65 ± 18 MBq (1.76 ± 0.50 mCi) (range 43.3 to 88.8 MBq) with a total mass of 
PET Results
Increased [
89 Zr]trastuzumab uptake was seen in at least one known lesion in 10 of the 12 subjects (Table 1) , including the primary tumor in 4 of 6 subjects before or undergoing neoadjuvant therapy and at least one lesion in all 6 subjects with metastatic disease. When the paired images were compared, the later time points had better image quality, with the best quality observed on days 4 and 6 after [ 89 Zr]trastuzumab administration ( Figs. 1 and 2 ). In the ten subjects who had abnormally increased [
89 Zr]trastuzumab uptake in one or more lesions, the intensity of tumor uptake relative to surrounding tissues increased at the later imaging time in all but one case.
Dosimetry
The tracer was predominantly retained in the liver and blood. Liver activity remained nearly constant over time at ∼12 % of the injected dose (ID). Slow blood clearance was observed with a biological half-life of 113 h and an initial level of 58 % ID. Cumulative organ time-activity curves are presented in Fig. 3 . For most organs, a rapid distribution of the tracer to the organ is observed immediately after injection (chiefly reflecting activity in blood) followed by constant activity concentration or slow clearance. The organ residence times are presented in Table 2 , and the human radiation dose estimates are presented in Table 3 . Because of its high retention, the liver is the critical (Fig. 2) .
Discussion
Systemic therapy of breast cancer includes cytotoxic chemotherapy, hormonal therapy, and targeted therapy to HER2. Accurate determination of HER2 status is essential for breast cancer treatment. However, HER2 status may change during the course of a patient's disease and may vary from one tumor site to another. Lower et al. reviewed 382 paired primary tumors and subsequent metastases and reported discordance in HER2 status in 33.2 % of paired samples overall; the primary tumor was positive and the metastatic site negative in 23.6 % and the converse was found in 9.6 % [14] . For these reasons, repeated biopsies have been encouraged; however, this is not always practical. Another challenge with biopsy-based determination of HER2 status is intratumoral heterogeneity [31] [32] [33] . Discordant HER2 expression within a single cancer or between different sites of cancer can introduce sampling error and confound treatment decision-making. PET-based measurement of HER2 expression using the radiolabeled mAb, [
89 Zr]trastuzumab, has several advantages over biopsy-based methods. PET directly assesses the availability of HER2 to be bound to trastuzumab; thus, it is potentially a more reliable predictor of response to trastuzumab therapy. In addition, PET has the ability to assess intratumoral heterogeneity of HER2 expression in a lesion (within the limits of resolution of PET) and intertumoral heterogeneity among multiple lesions in a patient. Moreover, because it is noninvasive, PET can be repeated during therapy to assess response. Several mechanisms of drug resistance to trastuzumab have been identified, and these can be divided into mechanisms that will alter trastuzumab binding versus intracellular protein or pathway changes that will not affect trastuzumab binding [34] . Drug resistance mechanisms that alter trastuzumab binding, such as production of a truncated HER2 protein that lacks the trastuzumab binding epitope, emergence of a low-HER2-expressing subclone, or inhibition of trastuzumab binding by overexpression of the MUC4-sialomucin complex, are potentially detectable with [
89 Zr]trastuzumab PET imaging [35, 36] . We acknowledge that drug resistance mechanisms that do not affect trastuzumab binding, such as PI3-kinase mutations, PTEN deletions, or activation of other tyrosine kinases, will not be detectable with [
89 Zr]trastuzumab PET imaging [37, 38] .
In this study, we evaluated the human radiation dosimetry, as well as the safety and imaging characteristics, of [ 89 Zr]trastuzumab in women with HER2-positive breast cancer. Human dosimetry estimates derived from murine biodistribution data were used to select the target ID for this human study. These data indicated a critical organ dose of 0.79 mSv/MBq to the heart wall reflecting the long retention time of the tracer in the blood and an ED of 0.44 mSv/MBq. Thus, total ED for two PET/CT imaging time points for dosimetry evaluation (from up to 92.5 MBq of [
89 Zr]trastuzumab and two lose-dose CT scans) was estimated to be 48.6 mSv.
In humans, we observed overall higher tracer residence times in all organs. Notably, the liver, kidney, and heart muscle (estimated from blood content) residence times are higher in humans indicating slower kinetics in humans relative to rodents. Supplemental Fig. 3 presents the comparative dosimetry of the animal data against the present human dosimetry. [
89 Zr]trastuzumab was found to be safe in this phase 0 study. We observed no adverse effects in any of our 12 subjects.
We found excellent delineation of tumor lesions by [ 89 Zr]trastuzumab PET/CT in woman with HER2-positive breast cancer, similar to the findings of the first-inhuman study of [ 89 Zr]trastuzumab, conducted by Djikers et al. [18] and to the findings of the ZEPHIR clinical trial recently published by Gebhart et al. [24] . The optimal imaging times were found to be comparable despite differences in the method of conjugation of the metal chelate for Zr-89 to trastuzumab. Another difference is the administered activity of [ 89 Zr]trastuzumab. Djikers et al. administered 37 MBq, whereas we administered almost twice that to allow for imaging up to 6 days post-injection (day 0 = injection day) without compromising image quality. Our studies show that a dosage of approximately 62 MBq of [ 89 Zr]trastuzumab in the presence of unlabeled trastuzumab (50 mg of trastuzumab in trastuzumab naive and 10 mg in patients already receiving trastuzumab) yielded good visualization of tumor foci at 6 days post-injection with acceptable dosimetry in normal organs (Fig. 1) . Finally, absence of [ 89 Zr]trastuzumab uptake in known lesions was observed in 7 of 14 subjects in the Djikers study and in 2 of 12 subjects of our study (Table 1) . More investigations are needed to determine whether the absence of tumor uptake reflects a reduction in HER2 overexpression as a consequence of trastuzumab therapy. The high dose 
